Literature DB >> 3729339

Pharmacokinetics and metabolism of [14C]rosaramicin in dogs.

C C Lin, H K Kim, A Marco, E Radwanski, S Symchowicz.   

Abstract

The pharmacokinetics and metabolism of [14C]rosaramicin were studied in dogs after intravenous (i.v.; 10 mg/kg [bodyweight]) and oral (25 mg/kg) administration. After i.v. administration, rosaramicin levels in plasma declined rapidly, with half-lives of 0.22 h for the distribution phase and 0.97 h for the elimination phase. The apparent volume of distribution was 3.43 liters/kg, and the total body clearance was 106 mg/min . kg, indicating extensive distribution in tissue or metabolism or both. The absorption of oral solution was 58%, and the absolute bioavailability of rosaramicin was 35%. The plasma area under the curve of unchanged rosaramicin was only 5% that of total radioactivity after oral administration and 8% after i.v. administration, indicating extensive metabolism of the drug. The total radioactivity excreted in urine accounted for only 24% of the i.v. dose and 17% of the oral dose. Fecal radioactivity accounted for 71% of the i.v. dose and 68% of the oral dose. Several metabolites were observed in the plasma and urine. The amount of unchanged rosaramicin in urine (1 to 2% of the dose) was quite small after drug administration by either route.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3729339      PMCID: PMC284148          DOI: 10.1128/AAC.29.5.753

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Antibiotics excretion in canine vaginal and urethral secretions.

Authors:  U Hoyme; A Baumueller; P O Madsen
Journal:  Invest Urol       Date:  1978-07

2.  Biological studies with rosamicin, a new Micromonospora-produced macrolide antibiotic.

Authors:  J A Waitz; C G Drube; E L Moss; M J Weinstein
Journal:  J Antibiot (Tokyo)       Date:  1972-11       Impact factor: 2.649

3.  A new Micromonospora-produced macrolide antibiotic, rosamicin.

Authors:  G H Wagman; J A Waitz; J Marquez; A Murawaski; E M Oden; R T Testa; M J Weinstein
Journal:  J Antibiot (Tokyo)       Date:  1972-11       Impact factor: 2.649

4.  Pharmacokinetics and metabolism of rosaramicin in humans.

Authors:  C C Lin; M Chung; R Gural; D Schuessler; H K Kim; E Radwanski; A Marco; C DiGiore; S Symchowicz
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

5.  High-pressure liquid chromatographic method for determination of rosaramicin in humans.

Authors:  C Lin; H Kim; D Schuessler; E Oden; S Symchowicz
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

6.  Isolation and identification of a metabolite of rosaramicin in human urine.

Authors:  C Lin; M S Puar; D Schuessler; B N Prananik; S Symchowicz
Journal:  Drug Metab Dispos       Date:  1984 Jan-Feb       Impact factor: 3.922

7.  Rosamicin--a new drug for the treatment of bacterial prostatitis.

Authors:  A Baumueller; U Hoyme; P O Madsen
Journal:  Antimicrob Agents Chemother       Date:  1977-08       Impact factor: 5.191

8.  Experimental models for determination of antimicrobials in prostatic tissue, interstitial fluid and secretion.

Authors:  P O Madsen; A Baumueller; U Hoyme
Journal:  Scand J Infect Dis Suppl       Date:  1978
  8 in total
  1 in total

Review 1.  Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part II).

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1989-05       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.